Resource Type

Journal Article 83

Year

2023 8

2022 4

2021 5

2020 2

2019 3

2018 3

2017 4

2016 5

2015 7

2014 7

2013 3

2012 3

2011 1

2010 7

2009 8

2008 5

2007 5

2006 1

open ︾

Keywords

hepatocellular carcinoma 23

nasopharyngeal carcinoma 6

Hepatocellular carcinoma 5

prognosis 5

carcinoma 4

HCC 3

diagnosis 3

esophageal squamous cell carcinoma 3

hepatocellular carcinoma (HCC) 3

immunotherapy 3

metastasis 3

E-cadherin 2

Epstein-Barr virus 2

Gut microbiota 2

biomarker 2

cisplatin 2

clinical 2

control 2

hypoxia 2

open ︾

Search scope:

排序： Display mode:

The impact of hypoxia in hepatocellular carcinoma metastasis

Carmen Chak-Lui Wong, Alan Ka-Lun Kai, Irene Oi-Lin Ng

Frontiers of Medicine 2014, Volume 8, Issue 1,   Pages 33-41 doi: 10.1007/s11684-013-0301-3

Abstract:

Hypoxia is a common phenomenon in hepatocellular carcinoma (HCC).Expression of HIF is closely associated with metastasis and poor prognosis in HCC.Because HIF is the central regulator of HCC metastasis, HIF inhibitors are attractive tools when usedalone or as combined treatment to curb HCC metastasis.This review will summarize the current findings on the impact of hypoxia/HIF in HCC, with a particular

Keywords： hypoxia     hepatocellular carcinoma (HCC)     metastasis     hypoxia-inducible factor (HIF)    

HTML PDF Collect

Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 551-573 doi: 10.1007/s11684-022-0928-z

Abstract: Patients with hepatocellular carcinoma (HCC) and bone metastasis (BM) suffer from greatly reduced lifeHowever, BM in HCC has long been overlooked possibly due to its relatively low prevalence in previousdate, no consensus or guidelines have been reached or formulated for the prevention and management of HCCThe risk factors, diagnosis, prognosis, and therapeutic approaches of HCC BM are detailed to provideWe also present the advances in the pathological and molecular mechanisms of HCC BM to shed light on

Keywords： HCC     bone     osteotropism     clinical     basic researches     advances    

HTML PDF Collect

Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric

Jianpeng Liu, Xinhua Chen, Shusen Zheng

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 170-177 doi: 10.1007/s11684-020-0747-z

Abstract: Recent animal experiments show that nsPEF can induce the immunogenic cell death of hepatocellular carcinoma(HCC) and stimulate the host’s immune response to kill residual tumor cells and decrease distant metastaticclinical importance because the nonthermal ablation may enhance the immune memory, which can prevent HCCinhibits the regulatory responses, thereby improving immune stimulation and limiting immunosuppression in HCC-bearingTherefore, nsPEF has excellent potential for HCC treatment.

Keywords： nanosecond pulsed electric fields (nsPEF)     hepatocellular carcinoma (HCC)     immune response     recurrence     metastasis    

HTML PDF Collect

polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellularcarcinoma risk

Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 217-226 doi: 10.1007/s11684-014-0326-2

Abstract: nbsp;gene and its multiplicative interactions with hepatitis B virus (HBV) mutations in the risk of hepatocellularcarcinoma (HCC).HBV surface antigen (HBsAg) seroclearance subjects, and 2011 HBsAg-positive subjects (including 1021 HCCperformed to test the associations of rs3783553, mutations, and their interactions with the risk of HCCseroclearance subjects, HBsAg-positive subjects without HCC, and all controls.

Keywords： hepatocellular carcinoma (HCC)     interaction     miRNA-122-binding site     IL-1A     rs3783553     hepatitis B virus (    

HTML PDF Collect

Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Review

Ze Xiang, Jian Wu, Jiarui Li, Shusen Zheng, Xuyong Wei, Xiao Xu

Engineering 2023, Volume 29, Issue 10,   Pages 59-72 doi: 10.1016/j.eng.2022.12.012

Abstract:

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver, posing a significant threatAlthough liver transplantation (LT) is an effective treatment for HCC, ischemia–reperfusion (I/with chronic liver disease that can develop into HCC as well as the diagnostic and prognostic valueof the gut microbiota in HCC.provide new insights into the management of HCC and LT via gut microbiota modulation.

Keywords： Gut microbiota     Hepatocellular carcinoma (HCC)     Liver transplantation (LT)     Clinical value     Mediating    

HTML PDF Collect

Towards the optimization of management of hepatocellular carcinoma

Xi Feng, Madhava Pai, Malkhaz Mizandari, Tinatin Chikovani, Duncan Spalding, Long Jiao, Nagy Habib

Frontiers of Medicine 2011, Volume 5, Issue 3,   Pages 271-276 doi: 10.1007/s11684-011-0148-4

Abstract: Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world, closely correlated withThe vast majority of HCC patients present at a late stage and are unsuitable for surgery due to limitedA series of new technologies have been developed to optimise HCC management.

Keywords： management     hepatocellular carcinoma (HCC)     radiofrequency (RF) ablation     laparoscopic liver resection     stem    

HTML PDF Collect

Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis

Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 183-190 doi: 10.1007/s11684-016-0440-4

Abstract: weighted gene coexpression network analysis (WGCNA) to gain insights into the molecular aspects of hepatocellularcarcinoma (HCC).In conclusion, gene signatures identified from the genome-based assays could contribute to HCC stratification

Keywords： hepatocellular carcinoma     coexpression     module     microarray     prognosis    

HTML PDF Collect

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Amy Lee, Fa-Chyi Lee

Frontiers of Medicine 2020, Volume 14, Issue 3,   Pages 273-283 doi: 10.1007/s11684-019-0728-2

Abstract: In terms of global cancer-related deaths, hepatocellular carcinoma (HCC) has the fourth highest mortalityUp until 2017, treatment of advanced HCC was largely limited to sorafenib, an oral tyrosine kinase inhibitorEven with this new variety, systemic treatment of advanced HCC remains largely unsatisfactory, and theThe expected breakthrough of using immune checkpoint inhibitors in advanced HCC did not materialize in, and there is hope for significant advances in the treatment of advanced HCC as the field continues

Keywords： hepatocellular carcinoma     tyrosine kinase inhibitor     check point inhibitor     anti-angiogenesis    

HTML PDF Collect

Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies

Lunxiu Qin

Frontiers of Medicine 2014, Volume 8, Issue 1,   Pages 24-32 doi: 10.1007/s11684-014-0312-8

Abstract: expression profiling study, OPN was identified as one of the leading genes associated with the metastasis of hepatocellularcarcinoma (HCC).We focused on OPN to evaluate its prognostic values and important roles in HCC metastasis.the leading independent prognostic factors for HCC patients, even in the early stage of HCC, and couldand is an attractive potential therapeutic target for combating HCC metastasis.

Keywords： osteopontin (OPN)     hepatocellular carcinoma     metastasis     prognosis     therapeutic target     biomarker     genetic    

HTML PDF Collect

Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic

Min Yu, Zonghai Li

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 509-521 doi: 10.1007/s11684-017-0546-3

Abstract:

Hepatocellular carcinoma (HCC) is currently the fifth most common malignancy and the third leadingIn the last few years, treatments for HCC have significantly improved from a mere surgical resectionchallenging clinical scenario warrants new effective and life-prolonging strategies for patients with HCC, indicating that HCC might be an ideal target for NK cell-based immunotherapies.To obtain comprehensive insights into the putative influence of NK cells on HCC, this paper summarizes

Keywords： natural killer cell     hepatocellular carcinoma     immunotherapy    

HTML PDF Collect

Advances in managing hepatocellular carcinoma

Marielle Reataza,David K. Imagawa

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 175-189 doi: 10.1007/s11684-014-0332-4

Abstract:

Multiple modalities for treatment of hepatocellular carcinoma are available, depending on tumor sizeCurrently, sorafenib is the only US Food and Drug Administration-approved chemotherapeutic for hepatocellularcarcinoma.This review serves to emphasize the current and new technologies emerging in the treatment of hepatocellularcarcinoma.

Keywords： hepatocellular carcinoma     radiofrequency ablation     microwave ablation     chemoembolization     radioembolization    

HTML PDF Collect

Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinoma

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 729-746 doi: 10.1007/s11684-022-0978-2

Abstract: The effect of anti-programmed cell death 1 (anti-PD-1) immunotherapy is limited in patients with hepatocellularcarcinoma (HCC).Yes-associated protein 1 (YAP1) expression increased in liver tumor cells in early HCC, and AkkermansiaHowever, the interaction between A. muciniphila abundance and YAP1 expression remains unclear in HCC

Keywords： hepatocellular carcinoma     YAP1     Akkermansia muciniphila     anti-PD-1     dihydroartemisinin     bile acid    

HTML PDF Collect

Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellularcarcinoma

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 467-482 doi: 10.1007/s11684-021-0869-y

Abstract: vascular endothelial growth factor receptor 2, is the second-line treatment for patients with advanced hepatocellularcarcinoma (HCC).In this study, we found that cMet-low HCC cells showed primary resistance to cMet inhibitors, and theumbilical vascular endothelial cells and human growth factor-induced invasion of cMet inhibitor-resistant HCCuncover a potential combination therapy of cabozantinib and rapamycin to combat cabozantinib-resistant HCC

Keywords： hepatocellular carcinoma     cabozantinib     primary resistance     rapamycin    

HTML PDF Collect

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 122-133 doi: 10.1007/s11684-012-0193-7

Abstract:

Hepatocellular carcinoma (HCC) is a highly complex disease that is generally resistant to commonlySuch research has led to identification of several potential molecular targets in HCC, and subsequently, development of novel systemic agents for the treatment of HCC has begun in earnest.In this article, we review the current knowledge of the molecular pathogenesis of HCC and outline potentialvarious components of the tumor microenvironment, as well as novel molecular and cellular targets in HCC

Keywords： hepatocellular carcinoma     molecular classification     molecular targeted therapies     tumor microenvironment    

HTML PDF Collect

Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated

Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 63-71 doi: 10.1007/s11684-014-0342-2

Abstract:

Cryoablation is a less prevalent percutaneous ablative therapy for hepatocellular carcinoma (HCC),We report our experience in treating 1595 HCC cases with percutaneous cryoablation to give a comprehensiveFrom January 2003 to December 2013, 1595 patients with 2313 HCC nodules were ablated with 2945 cryoablation

Keywords： hepatocellular carcinoma     percutaneous cryoablation     efficacy     safety    

HTML PDF Collect

Title Author Date Type Operation

The impact of hypoxia in hepatocellular carcinoma metastasis

Carmen Chak-Lui Wong, Alan Ka-Lun Kai, Irene Oi-Lin Ng

Journal Article

Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives

Journal Article

Immune response triggered by the ablation of hepatocellular carcinoma with nanosecond pulsed electric

Jianpeng Liu, Xinhua Chen, Shusen Zheng

Journal Article

polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellularcarcinoma risk

Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen

Journal Article

Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and

Ze Xiang, Jian Wu, Jiarui Li, Shusen Zheng, Xuyong Wei, Xiao Xu

Journal Article

Towards the optimization of management of hepatocellular carcinoma

Xi Feng, Madhava Pai, Malkhaz Mizandari, Tinatin Chikovani, Duncan Spalding, Long Jiao, Nagy Habib

Journal Article

Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis

Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu

Journal Article

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Amy Lee, Fa-Chyi Lee

Journal Article

Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies

Lunxiu Qin

Journal Article

Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic

Min Yu, Zonghai Li

Journal Article

Advances in managing hepatocellular carcinoma

Marielle Reataza,David K. Imagawa

Journal Article

Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinoma

Journal Article

Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellularcarcinoma

Journal Article

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Journal Article

Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated

Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang

Journal Article